Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026

Dogwood Therapeutics, Inc.

Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).
Cash $6.5M at Dec 31, 2025; Jan 2026 financing raised $11.4M net to fund through Phase 2b readout.
Halneuron CINP Phase 2b >50% enrolled; interim analysis showed separation from placebo; top-line expected Q3 2026.
R&D expenses FY 2025 $21.8M (up from $3.5M) due to $12.0M SP16 license fee and clinical trial costs.
G&A expenses fell to $6.1M from $8.7M due to lower nonrecurring transaction costs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Dogwood Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to common stockholders for the fourth quarter of 2025 was $3.8 million, EPS or $0.26 basic and diluted net loss per share.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss attributable to common stockholders for the fourth quarter of 2025 was $3.8 million
EPS: or $0.26 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dogwood Therapeutics, Inc. reported Year ended December 31, 2025 results: net income Net loss attributable to common stockholders for the year ended December 31, 2025 was $35.5 million, EPS or $7.13 basic and diluted net loss per share.

Period: Year ended December 31, 2025
Net income: Net loss attributable to common stockholders for the year ended December 31, 2025 was $35.5 million
EPS: or $7.13 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the year ended December 31, 2025 was $35.5 million, or $7.13 basic and diluted net loss per share

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-029992

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.